Known or suspected OSA should be considered an independent risk factor for difficult intubation, difficult mask ventilation, or a combination of both. Adequate difficult airway management precautions should be taken. (1B)

Patients with OSA who received neuromuscular blocking agents may be at increased risk of effects of postoperative residual neuromuscular blockade, hypoxemia, or respiratory failure. (2C)

there is insufficient evidence to suggest the preference of any neuromuscular blocking reversal agent to reduce the risks of postoperative respiratory complications in patients with OSA（Evidence level:C；Recommendation grade:NA）.

Patients with OSA may be at increased risk for adverse respiratory events from the use of opioid medication. (2C)

The possibility of altered pain perception in patients with OSA should be considered. (2C)

Patients with OSA may be at increased risk for adverse respiratory events from the use of propofol for procedural sedation. (1B)

There is a lack of evidence to assess residual effects of inhalational anesthetic agents in the population with OSA（Evidence level:B；Recommendation grade:No Recommendation）.

The indications for pharmacological premedication are the same for MH-susceptible patients as those not predisposed to MH. (1C)

Minimum monitoring for general anaesthesia for an MHsusceptible patient is electrocardiography, pulse oximetry, noninvasive blood pressure, inspired oxygen concentration, inspired/expired CO2 with capnography, airway pressure, ventilatory frequency, minute ventilation, peripheral nerve stimulator when neuromuscular blocking agents are used, and continuous core body temperature measurement for procedures of any duration and (where available) depth of anaesthesia monitoring. (1C)

If trigger-free anaesthesia is provided, an MH-susceptible patient will not need any extra monitoring during anaesthesia compared with a patient with the same condition and preoperative status, but not predisposed to MH. (1C)